{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:43:48Z","timestamp":1762875828408},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T00:00:00Z","timestamp":1482537600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00277-016-2897-2","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T22:07:41Z","timestamp":1482617261000},"page":"461-467","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone"],"prefix":"10.1007","volume":"96","author":[{"given":"Noam","family":"Benyamini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eldad J.","family":"Dann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsila","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Lavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,24]]},"reference":[{"key":"2897_CR1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875\u20131883","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"2897_CR2","doi-asserted-by":"crossref","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","volume":"24","author":"P Moreau","year":"2013","unstructured":"Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, Dreyling M (2013) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi133\u2013vi137","journal-title":"Ann Oncol"},{"key":"2897_CR3","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.exphem.2006.06.022","volume":"34","author":"JF Jacoub","year":"2006","unstructured":"Jacoub JF, Suryadevara U, Pereyra V, Colon D, Fontelonga A, Mackintosh FR, Hall SW, Ascensao JL (2006) Mobilization strategies for the collection of peripheral blood progenitor cells: results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Exp Hematol 34:1443\u20131450","journal-title":"Exp Hematol"},{"key":"2897_CR4","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","volume":"23","author":"S Giralt","year":"2009","unstructured":"Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG (2009) International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23:1904\u20131912","journal-title":"Leukemia"},{"key":"2897_CR5","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.bmt.1703575","volume":"29","author":"DS Allan","year":"2002","unstructured":"Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH (2002) Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 29:967\u2013972","journal-title":"Bone Marrow Transplant"},{"key":"2897_CR6","first-page":"49","volume":"12","author":"JM Boiron","year":"1993","unstructured":"Boiron JM, Marit G, Faberes C, Cony-Makhoul P, Foures C, Ferrer AM, Cristol G, Sarrat A, Girault D, Reiffers J (1993) Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 12:49\u201355","journal-title":"Bone Marrow Transplant"},{"key":"2897_CR7","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","volume":"18","author":"D Sheppard","year":"2012","unstructured":"Sheppard D, Bredeson C, Allan D, Tay J (2012) Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant 18:1191\u20131203","journal-title":"Biol Blood Marrow Transplant"},{"key":"2897_CR8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","volume":"27","author":"O Fitoussi","year":"2001","unstructured":"Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A, Agape P, Nicolini F, Dazey B, Reiffers J, Salmi R, Marit G (2001) A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 27:837\u2013842","journal-title":"Bone Marrow Transplant"},{"key":"2897_CR9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/14653240701452800","volume":"9","author":"DK Hiwase","year":"2007","unstructured":"Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP (2007) Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 9:539\u2013547","journal-title":"Cytotherapy"},{"key":"2897_CR10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1701910","volume":"24","author":"F Lefrere","year":"1999","unstructured":"Lefrere F, Makke J, Fermand J, Marolleau J, Dal Cortivo L, Alberti C, Mouton V, Benbunan M, Miclea J (1999) Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma. Bone Marrow Transplant 24:463\u2013466","journal-title":"Bone Marrow Transplant"},{"key":"2897_CR11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000070967","volume":"109","author":"MT Petrucci","year":"2003","unstructured":"Petrucci MT, Avvisati G, La Verde G, De Fabritiis P, Ribersani M, Palumbo G, De Felice L, Rusignuolo A, Simone F, Meloni G, Mandelli F (2003) Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma. Acta Haematol 109:184\u2013188","journal-title":"Acta Haematol"},{"key":"2897_CR12","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/leu.2010.82","volume":"24","author":"P Moreau","year":"2010","unstructured":"Moreau P, Hulin C, Marit G, Caillot D, Facon T, Lenain P, Berthou C, Pegourie B, Stoppa AM, Casassus P, Michallet M, Benboubker L, Maisonneuve H, Doyen C, Leyvraz S, Mathiot C, Avet-Loiseau H, Attal M, Harousseau JL (2010) Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 24:1233\u20131235","journal-title":"Leukemia"},{"key":"2897_CR13","doi-asserted-by":"crossref","unstructured":"Brioli A, Perrone G, Volpe S, Pasini S, Mele A, Rossini F, Liberati AM, De Rosa L, Avvisati G, Amadori G, Gozzetti A, Capaldi A, Mele G, Farina G, Zamagni E, Vigna E, Capalbo S, Magni M, Nunziata GR, Crugnola M, Fregoni V, Leopardi G, Attolico I, Moscetti A, Podda L, Pregno P, Baccarani M, Cavo M (2011) Autologous peripheral blood stem-cell (PBSC) collection is not impaired by bortezomib-thalidomide-dexamethasone (VTD) induction therapy in newly diagnosed multiple myeloma (MM). Blood 118(317a)","DOI":"10.1182\/blood.V118.21.317.317"},{"key":"2897_CR14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2141.2010.08313.x","volume":"150","author":"MA Gertz","year":"2010","unstructured":"Gertz MA (2010) Current status of stem cell mobilization. Br J Haematol 150:647\u2013662","journal-title":"Br J Haematol"},{"key":"2897_CR15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","volume":"43","author":"MA Gertz","year":"2009","unstructured":"Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Gastineau DA, Winters JL, Litzow MR (2009) Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 43:619\u2013625","journal-title":"Bone Marrow Transplant"},{"key":"2897_CR16","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621\u20134629","journal-title":"J Clin Oncol"},{"key":"2897_CR17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","volume":"23","author":"CB Reeder","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23:1337\u20131341","journal-title":"Leukemia"},{"key":"2897_CR18","unstructured":"Jang JE, Cheong JW, Kim SJ, Cho H, Suh C, Lee H, Eom HS, Yhim HY, Lee WS, Min CK, Lee JH, Park JS, Kim JS (2015) Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. Leuk Lymphoma:1\u20139"},{"key":"2897_CR19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"2897_CR20","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B,Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117:4691\u20134695","journal-title":"Blood"},{"key":"2897_CR21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","volume":"18","author":"VH Jimenez-Zepeda","year":"2012","unstructured":"Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S, Chen C, Kukreti V, Reece DE (2012) Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 18:773\u2013779","journal-title":"Biol Blood Marrow Transplant"},{"key":"2897_CR22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.11644","volume":"93","author":"HM Lokhorst","year":"2008","unstructured":"Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H (2008) Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93:124\u2013127","journal-title":"Haematologica"},{"key":"2897_CR23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bmt.2008.410","volume":"43","author":"W Bensinger","year":"2009","unstructured":"Bensinger W, DiPersio JF, McCarty JM (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 43:181\u2013195","journal-title":"Bone Marrow Transplant"},{"key":"2897_CR24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2011.197","volume":"26","author":"MP Rettig","year":"2012","unstructured":"Rettig MP, Ansstas G, DiPersio JF (2012) Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 26:34\u201353","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2897-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T06:35:16Z","timestamp":1601274916000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2897-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,24]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2897-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,24]]}}}